305 related articles for article (PubMed ID: 25684563)
21. Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models.
Schnabl B; Farshchi-Heydari S; Loomba R; Mattrey RF; Hoh CK; Sirlin CB; Brenner DA; Behling CA; Vera DR
Nucl Med Biol; 2016 Feb; 43(2):179-87. PubMed ID: 26872443
[TBL] [Abstract][Full Text] [Related]
22. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
[TBL] [Abstract][Full Text] [Related]
24. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis.
Cengiz M; Ozenirler S; Kocabiyik M
Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):57-63. PubMed ID: 26513612
[TBL] [Abstract][Full Text] [Related]
25. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
[TBL] [Abstract][Full Text] [Related]
26. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.
Kruger FC; Daniels CR; Kidd M; Swart G; Brundyn K; van Rensburg C; Kotze M
S Afr Med J; 2011 Jun; 101(7):477-80. PubMed ID: 21920102
[TBL] [Abstract][Full Text] [Related]
27. Should a liver biopsy be done in patients with subclinical chronically elevated transaminases?
de Lédinghen V; Combes M; Trouette H; Winnock M; Amouretti M; de Mascarel A; Couzigou P
Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):879-83. PubMed ID: 15316412
[TBL] [Abstract][Full Text] [Related]
28. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
[TBL] [Abstract][Full Text] [Related]
29. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease.
Koo BK; Um SH; Seo DS; Joo SK; Bae JM; Park JH; Chang MS; Kim JH; Lee J; Jeong WI; Kim W
Liver Int; 2018 Apr; 38(4):695-705. PubMed ID: 28898507
[TBL] [Abstract][Full Text] [Related]
30. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
[TBL] [Abstract][Full Text] [Related]
32. A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects.
Giraudi PJ; Gambaro SE; Ornelas Arroyo S; Chackelevicius CM; Giuricin M; Silvestri M; Macor D; Crocé LS; Bonazza D; Soardo G; de Manzini N; Zanconati F; Tiribelli C; Palmisano S; Rosso N
Liver Int; 2018 Jan; 38(1):155-163. PubMed ID: 28650518
[TBL] [Abstract][Full Text] [Related]
33. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis.
Bahcecioglu IH; Yalniz M; Ataseven H; Ilhan N; Ozercan IH; Seckin D; Sahin K
Hepatogastroenterology; 2005; 52(65):1549-53. PubMed ID: 16201116
[TBL] [Abstract][Full Text] [Related]
34. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease.
Kapil S; Duseja A; Sharma BK; Singla B; Chakraborti A; Das A; Ray P; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2016 Jan; 31(1):213-21. PubMed ID: 26212089
[TBL] [Abstract][Full Text] [Related]
35. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis.
Tsang SW; Ng WF; Wu BP; Chow DA; Li ET; Wong TC
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):116-21. PubMed ID: 16706822
[TBL] [Abstract][Full Text] [Related]
36. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M
Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489
[TBL] [Abstract][Full Text] [Related]
37. [Clinical and histological features of non-alcoholic fatty liver disease].
Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
[TBL] [Abstract][Full Text] [Related]
38. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test.
Korkmaz H; Unler GK; Gokturk HS; Schmidt WE; Kebapcilar L
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1137-43. PubMed ID: 26049707
[TBL] [Abstract][Full Text] [Related]
39. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
40. Analytical, anthropometric and dietary factors associated with the development of fibrosis in patients with nonalcoholic fatty liver disease.
Gómez de la Cuesta S; Aller de la Fuente R; Tafur Sánchez C; Izaola O; García Sánchez C; Mora N; González Hernández JM; de Luis Román D
Rev Esp Enferm Dig; 2018 May; 110(5):292-298. PubMed ID: 29338271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
